DNLI
Denali Therapeutics
$18.66
+$0.25 (+1.36%)Oct 26, 2026
Key metrics
The numbers that frame DNLI today
- Market cap
- $2.98B
- Gross margin
- 97.4%
- EV / Sales
- 836.3
- ROIC
- -53.6%
- Div yield
- 0%
- Debt / equity
- 0.3
- 52wk Low
- $13.75
- 52wk High
- $27.30
Growth
Revenue and earnings trend for DNLI
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about DNLI
Is Denali Therapeutics a good buy?
Hold. Denali Therapeutics has strong momentum, but poor quality makes the setup mixed. Growth looks poor. That could put pressure on the long-term business case. We think Denali Therapeutics is selling at a very high price.
What is the market capitalization of DNLI?
Denali Therapeutics's market capitalization is $2.98B.
What is the 52-week high for DNLI stock?
The 52-week high for Denali Therapeutics is $27.30. The current close of $18.66 is 31.6% below that high.
What is the 52-week low for DNLI stock?
The 52-week low for Denali Therapeutics is $13.75. The current close of $18.66 is 35.7% above that low.
Does DNLI stock pay dividends?
Denali Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for DNLI?
Denali Therapeutics's Debt / Equity ratio is 0.28.